Ligand Pharmaceuticals Incorporated · NASDAQ:LGND

Reardon Andrew sold 5,000 Ligand Pharmaceuticals Incorporated shares (Form 4)

Traded Nov 2, 2026 · Filed Nov 4, 2026

On Nov 2, 2026, Reardon Andrew (CLO & Secretary) sold 5,000 Ligand Pharmaceuticals Incorporated shares at an average US$313.22 for US$1.57M under a trading plan, leaving 31,854 shares. Filed Nov 4, 2026 (Form 4).

Sold
5,000 shares
Price
US$313.22 average (US$307.39 to US$323.14)
Value
US$1.57M
Holding after
31,854 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CLO & Secretary

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Nov 2, 2026Common StockOption exercise5,000US$52.2736,854Direct
Nov 2, 2026Common StockSale283US$307.3936,571Direct
Nov 2, 2026Common StockSale708US$308.4335,863Direct
Nov 2, 2026Common StockSale522US$309.9135,341Direct
Nov 2, 2026Common StockSale490US$310.6134,851Direct
Nov 2, 2026Common StockSale520US$311.7234,331Direct
Nov 2, 2026Common StockSale634US$312.8533,697Direct
Nov 2, 2026Common StockSale403US$313.7533,294Direct
Nov 2, 2026Common StockSale80US$314.5833,214Direct
Nov 2, 2026Common StockSale280US$317.9132,934Direct
Nov 2, 2026Common StockSale440US$318.7332,494Direct
Nov 2, 2026Common StockSale320US$319.9732,174Direct
Nov 2, 2026Common StockSale200US$321.4431,974Direct
Nov 2, 2026Common StockSale120US$323.1431,854Direct

Source

Download original · View original at SEC

Related